Delivery Order SPE2DR25D2007-SPE2DR26FM33E
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a delivery order valued at $4,470.48 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed price, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,982.70 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement therapy. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement with an ultimate completion date of December 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location and serve as the prime contractor for this...
- The Defense Logistics Agency awarded a delivery order valued at $7,157.88 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on January 2, 2026, with an ultimate completion date of January 5, 2026. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules valued at $2,554.80, with an ultimate completion date of December 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with the agency. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $10,494.25 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on November 17, 2025, with completion expected by November 18, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of the vendor's pharmaceutical supply support to federal military and healthcare systems. The contract was executed under a non-set-aside procurement process, underscoring AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $70,439.09 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme supplement) in 100-count bottles. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price and an ultimate completion date of September 3, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $9,788.44. This is a firm fixed price delivery order with an ultimate completion date of October 30, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. The award was made without a set-aside designation, indicating that AmerisourceBergen competed for this order on an open basis. This...
- The Defense Logistics Agency awarded a delivery order valued at $10,850.92 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on August 27, 2025, with an ultimate completion date of August 28, 2025. This non-set-aside, firm fixed-price delivery order represents a direct procurement of pharmaceutical supplies to support military and federal healthcare operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s, valued at $4,258.00, with an ultimate completion date of December 9, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a discrete delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The place of performance is AmerisourceBergen's corporate office location...
- SPE2DR25D2007Indefinite Delivery Contract
- SPE2DR25D2007-SPE2DR26FM33EDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,292.79 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on January 2, 2026, with an ultimate completion date of January 5, 2026. This competitively awarded, firm fixed-price delivery order represents a routine pharmaceutical procurement with no set-aside designation. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medical commodities including specialty medications, brand-name and generic drugs, and related supplies to support military healthcare programs and the Defense Health Agency. The company's extensive federal contract portfolio demonstrates its established capability to meet competitive procurement requirements and serve as a strategic vendor for federal medical supply needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 1/1/26 |